Answers are grounded in this paper and cite their sources.
Pancreatic cancer is malignant and highly lethal, largely due to a dense, fibrotic tumor stroma that fosters a profoundly immunosuppressive microenvironment and obstructs drug delivery. To overcome these barriers, we developed a novel recombinant human serum albumin-based nanoparticle encapsulating dimyristoyl GEM (dm-rHSA-NPs). In vivo, dm-rHSA-NPs achieved significant tumor accumulation with the assistance of extended half-life (3.91 vs. 0.82 h, vs. GEM) and tumor targeting ability of the rHSA-based nanoparticles. Upon reaching the tumor tissue, dm-rHSA-NPs exhibited highly efficient tumor penetration and fibrotic stroma degradation, leading to adequate cellular accumulation, further assisting in improved cellular apoptosis, decreased cellular migration and invasion, as well as ICD-inducing ability. Benefiting from these effects, the profound immunosuppression characteristic of pancreatic cancer was relieved, promoting DCs maturation (22-fold), increasing infiltration of CTLs (45-fold), and decreasing the infiltration of Tregs (3.9-fold) in the tumor. All these synergistic effects contributed to the excellent in vivo anti-pancreatic cancer efficacy (89% vs. 37% of the tumor-inhibition rate), an outstanding tumor metastasis inhibition ability (2 vs. 22 of the tumor metastasis sites), and negligible systemic toxicity, superior to GEM. By combining enhanced drug delivery with potent TME remodeling and immune activation, dm-rHSA-NPs represent a promising formulation with high potential in clinical application to treat pancreatic cancer.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: